Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind randomized study of atezolizumab versus placebo as adjuvant therapy in high-risk muscle-invasive urothelial bladder cancer
2020-004418-36Phase 3Active
- Sponsor
- Roche
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma of the bladder (TCC) and muscle-invasive bladder cancer (MIBC) comparing Atezolizumab with Placebo (2 arms). Primary endpoint: Investigator-assessed disease-free survival (DFS) in ctDNA-positive patients. Started Feb 2021; status: active.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma of the bladder (TCC)muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on 2020-004418-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004418-36.